Welcome to a very special edition of Conversations on MS! This session features three MS-specialist neurologists answering frequently asked questions. Dr. John Corboy moderates the event. Corboy is the Medical…
Read More
The MS Center’s Tom Stewart, M.S., PA-C, J.D. presents an informative webinar on two important topics for Colorado residents. Stewart provides a review of Colorado’s new paid Family Medical…
We are saddened to share that Dr. Jack Burks passed away on November 18, 2022. Dr. Burks was a core founder of the Rocky Mountain MS Center, and was at…
NfL and GFAP as Measures of Disease Progression Prospective study to evaluate Neurofilament Light (NfL) and glial fibrillary acidic protein (GFAP) as biomarkers for disease progression over time in patients…
Biomarkers are biological markers that can be used in diagnosis, selecting treatments, and evaluating treatment responses. Having pre-collected samples is invaluable for this research, and the Biobank ensures that researchers…
A whole new family of drugs is currently being studied very aggressively for the treatment of MS: Tyrosine kinases Inhibitors. Tyrosine kinases (TYKs) are intracellular enzymes that play a key…
A biomarker is any measurable indicator that can reliably and accurately tell us about a biological state or medical condition. As we continue to learn more about MS and utilize…
With current disease modifying therapies (DMTs) we have several highly effective treatments that work for many people, but there is a percentage of the population for whom these medications do…
Repair of MS damage and the potential for the reversal of the effects of MS are always on the minds of doctors, researchers and those living with the disease. Despite…
Over the past several months, there has been increased interest in the relationship between the Epstein Barr Virus and multiple sclerosis. A study conducted by a Harvard University research team…